PRESCRIPTION FOR CONFLICT: WHY THE ALLIANCE BETWEEN THE PHARMACEUTICAL INDUSTRY AND THE ANTI-TOBACCO MOVEMENT IS NOT IN THE BEST INTERESTS OF SMOKERS

Authors


Patrick Basham is the founding Director of the Democracy Institute, a Washington-based public policy research organisation (pbasham@democracyinstitute.org).

John C. Luik is a senior fellow at the Democracy Institute, Washington.

Abstract

Large pharmaceutical companies are major funders of anti-smoking lobby groups. The same firms manufacture the products used in Nicotine Replacement Therapy (NRT) and stand to gain when governments recommend this approach to smoking cessation. There is growing evidence, however, that NRT is less effective than ‘cold turkey’ methods, and, indeed, that it has a number of harmful side effects. Its continued promotion, together with counterproductive anti-smoking measures, raises serious questions about the influence of special interests over tobacco policy.

Ancillary